BioCentury | Jan 8, 2021
Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

The reckoning that will come after the pandemic will see broad if not tectonic shifts in drug development, from clinical trial conduct to scientific publishing, according to bioethicist Arthur Caplan....
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...
BioCentury | Dec 15, 2020
Product Development

Vaccines march forward & CAR Ts move earlier: a BioCentury podcast

On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the latest advances and setbacks among COVID-19 vaccines in the wake of FDA’s emergency use authorization on Friday for Pfizer and BioNTech’s...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...
BioCentury | Dec 1, 2020
Product Development

Moderna moves & Immunocore breaks through: a BioCentury podcast

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...
BioCentury | Nov 26, 2020
Product Development

U.S. government spending on Abbott BinaxNOW outstrips other rapid COVID-19 tests: Data Byte

Abbott’s BinaxNOW test has replaced its predecessor as the Trump Administration’s favorite COVID-19 test. A fact sheet released by HHS Tuesday showed the U.S. federal government has spent $760 million on the antigen test from Abbott...
BioCentury | Nov 14, 2020
Product Development

Denali holds gains after first human proof of concept for brain delivery tech

...I/II trial of DNL310, also called enzyme transport vehicle ETV:IDS...
...because the therapy delivers the missing enzyme IDS. ...
...sclerosis (ALS), Parkinson’s and Alzheimer’s.TARGETSIDS —Iduronate 2-sulfatase Selina Koch DNL310 (ETV:IDS) Denali...
BioCentury | Nov 2, 2020

Realignment around acquired NK assets primed Kiadis for €308M Sanofi buyout

A modestly-priced acquisition of an NK cell platform company in spring 2019 set up Kiadis for a premium takeout by its partner Sanofi, even after the Dutch biotech discontinued its lead T cell program late...
BioCentury | Oct 27, 2020

SPACs & vax: a BioCentury podcast

Once much maligned, special purpose acquisition companies have become a viable path to the public markets for top-tier biotechs this year. On the latest BioCentury This Week podcast, BioCentury editors...
BioCentury | Oct 21, 2020
Product Development

UCSF’s virus-host protein interaction maps ID targets for COVID-19, future coronaviruses

A UCSF-led team has identified host pathways that could inform development of countermeasures against future coronaviruses, as they interact with multiple coronaviruses that recently made the leap...
Items per page:
1 - 10 of 755